Lei Shi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lei Shi has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Koby Kidder
Program of Immunology and Molecular Cellular Biology, Department of Biology, Georgia State University, Atlanta, GA 30302, USA
4 shared publications- Yuan Liu
Department of Emergency, Nanjing Drum Tower Hospital, State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University School of Life Sciences, Nanjing, Jiangsu 210046, China
4 shared publications Zhen Bian
Program of Immunology and Molecular Cellular Biology, Department of Biology, Georgia State University, Atlanta, GA 30302, USA
3 shared publications- Youshe Ren
College of Animal Science, Shanxi Agricultural University, Taigu 030801, China
2 shared publications Charlie Garnett-Benson
Program of Cancer and Immunology, Georgia State University, Atlanta, USA
1 shared publication- Chunxiang Zhang
Tianjin Key Laboratory of Oral and Maxillofacial Function Reconstruction
1 shared publication
Latest Publications
- Open Access
- 21 November 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 28 (43) , 6109-6130
Differential analysis of intestinal microbiota and metabolites in mice with dextran sulfate sodium-induced colitis
Differential analysis of intestinal microbiota and metabolites in mice with dextran sulfate sodium-induced colitis
- 21 November 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 28 (43) , 6109-6130
Open AccessDifferential analysis of intestinal microbiota and metabolites in mice with dextran sulfate sodium-induced colitis
Differential analysis of intestinal microbiota and metabolites in mice with dextran sulfate sodium-induced colitis
- 28 September 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 14 (702) , eabb3966
SIRPα sequesters SHP-2 to promote IL-4 and IL-13 signaling and the alternative activation of macrophages
SIRPα enhances macrophage alternative activation by preventing a phosphatase from acting on cytokine receptors.
- 28 September 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 14 (702) , eabb3966
SIRPα sequesters SHP-2 to promote IL-4 and IL-13 signaling and the alternative activation of macrophages
SIRPα enhances macrophage alternative activation by preventing a phosphatase from acting on cytokine receptors.
- 1 September 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 207 (5) , 1419-1427
Non-Lyn Src Family Kinases Activate SIRPα–SHP-1 to Inhibit PI3K–Akt2 and Dampen Proinflammatory Macrophage Polarization
Macrophage functional plasticity plays a central role in responding to proinflammatory stimuli. The molecular basis underlying the dynamic phenotypic activation of macrophages, however, remains incompletely understood. In this article, we report that SIRPα is a chief negative regulator of proinflammatory macrophage polarization. In response to TLR agonists, proinflammatory cytokines, or canonical M1 stimulation, Src family kinases (SFK) excluding Lyn phosphorylate SIRPα ITIMs, leading to the preferential recruitment and activation of SHP-1, but not SHP-2. Solely extracellular ligation of SIRPα by CD47 does not greatly induce phosphorylation of SIRPα ITIMs, but it enhances proinflammatory stimuli–induced SIRPα phosphorylation. Examination of downstream signaling elicited by IFN-γ and TLR3/4/9 agonists found that SIRPα-activated SHP-1 moderately represses STAT1, NF-κB, and MAPK signaling but markedly inhibits Akt2, resulting in dampened proinflammatory cytokine production and expression of Ag presentation machinery. Pharmacological inhibition of SHP-1 or deficiency of SIRPα conversely attenuates SIRPα-mediated inhibition and, as such, augments macrophage proinflammatory polarization that in turn exacerbates proinflammation in mouse models of type I diabetes and peritonitis. Our results reveal an SFK–SIRPα–SHP-1 mechanism that fine-tunes macrophage proinflammatory phenotypic activation via inhibition of PI3K–Akt2, which controls the transcription and translation of proinflammatory cytokines, Ag presentation machinery, and other cellular programs.
- 1 September 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 207 (5) , 1419-1427
Non-Lyn Src Family Kinases Activate SIRPα–SHP-1 to Inhibit PI3K–Akt2 and Dampen Proinflammatory Macrophage Polarization
Macrophage functional plasticity plays a central role in responding to proinflammatory stimuli. The molecular basis underlying the dynamic phenotypic activation of macrophages, however, remains incompletely understood. In this article, we report that SIRPα is a chief negative regulator of proinflammatory macrophage polarization. In response to TLR agonists, proinflammatory cytokines, or canonical M1 stimulation, Src family kinases (SFK) excluding Lyn phosphorylate SIRPα ITIMs, leading to the preferential recruitment and activation of SHP-1, but not SHP-2. Solely extracellular ligation of SIRPα by CD47 does not greatly induce phosphorylation of SIRPα ITIMs, but it enhances proinflammatory stimuli–induced SIRPα phosphorylation. Examination of downstream signaling elicited by IFN-γ and TLR3/4/9 agonists found that SIRPα-activated SHP-1 moderately represses STAT1, NF-κB, and MAPK signaling but markedly inhibits Akt2, resulting in dampened proinflammatory cytokine production and expression of Ag presentation machinery. Pharmacological inhibition of SHP-1 or deficiency of SIRPα conversely attenuates SIRPα-mediated inhibition and, as such, augments macrophage proinflammatory polarization that in turn exacerbates proinflammation in mouse models of type I diabetes and peritonitis. Our results reveal an SFK–SIRPα–SHP-1 mechanism that fine-tunes macrophage proinflammatory phenotypic activation via inhibition of PI3K–Akt2, which controls the transcription and translation of proinflammatory cytokines, Ag presentation machinery, and other cellular programs.
- Open Access
SIRPα sequesters SHP-2 to promote IL-4/13 signaling and alternative activation of macrophages
The Th2 cytokines IL-4 and IL-13 through activation of their shared receptor IL-4Rα direct macrophage alternative activation to promote immunosuppression and wound healing. However, the mechanisms that control macrophage responses to IL-4/13 are not fully understood. Apart from driving JAK-STAT and PI3K-Akt pathways to polarize macrophages toward the alternative phenotype, the activated IL-4/13 receptors recruit negative regulators SHP-1 and SHP-2, which dephosphorylate IL-4Rα and decrease its signaling. Here we report that SIRPα spatially restricts SHP-2 and, by such, promotes IL-4/13 signaling and macrophage alternative activation. SIRPα executes this regulation via its cytoplasmic ITIMs/ITSMs that undergo phosphorylation by IL-4/13-induced, Src kinase-activated Bruton’s tyrosine kinase (Btk), resulting in recruitment of SHP-2 and preclusion of SHP-2 from binding to and inhibiting IL-4/13 receptors. Despite that this regulation occurs independent of CD47, extracellular CD47 ligation of SIRPα facilitates its cytoplasmic phosphorylation and SHP-2 sequestration, leading to stronger IL-4/13 signaling and enhanced macrophage expression of IL-10, TGFβ, CD206, arginase-1, etc. Conversely, deficiency of SIRPα allows SHP-2 to freely bind to γC or IL-13Rα1 and through which dephosphorylate IL-4Rα, dampening its signaling. Consistent with these findings, impaired wound healing in Sirpα −/− mice under experimental colitis correlated with a deficit of immunosuppressive macrophages in the colon, a condition that was corrected by transfusion of ex vivo-produced SIRPα high alternatively activated macrophages.
Open AccessSIRPα sequesters SHP-2 to promote IL-4/13 signaling and alternative activation of macrophages
The Th2 cytokines IL-4 and IL-13 through activation of their shared receptor IL-4Rα direct macrophage alternative activation to promote immunosuppression and wound healing. However, the mechanisms that control macrophage responses to IL-4/13 are not fully understood. Apart from driving JAK-STAT and PI3K-Akt pathways to polarize macrophages toward the alternative phenotype, the activated IL-4/13 receptors recruit negative regulators SHP-1 and SHP-2, which dephosphorylate IL-4Rα and decrease its signaling. Here we report that SIRPα spatially restricts SHP-2 and, by such, promotes IL-4/13 signaling and macrophage alternative activation. SIRPα executes this regulation via its cytoplasmic ITIMs/ITSMs that undergo phosphorylation by IL-4/13-induced, Src kinase-activated Bruton’s tyrosine kinase (Btk), resulting in recruitment of SHP-2 and preclusion of SHP-2 from binding to and inhibiting IL-4/13 receptors. Despite that this regulation occurs independent of CD47, extracellular CD47 ligation of SIRPα facilitates its cytoplasmic phosphorylation and SHP-2 sequestration, leading to stronger IL-4/13 signaling and enhanced macrophage expression of IL-10, TGFβ, CD206, arginase-1, etc. Conversely, deficiency of SIRPα allows SHP-2 to freely bind to γC or IL-13Rα1 and through which dephosphorylate IL-4Rα, dampening its signaling. Consistent with these findings, impaired wound healing in Sirpα −/− mice under experimental colitis correlated with a deficit of immunosuppressive macrophages in the colon, a condition that was corrected by transfusion of ex vivo-produced SIRPα high alternatively activated macrophages.
- Open Access
- 28 May 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-16
Intratumoral SIRPα-deficient macrophages activate tumor antigen-specific cytotoxic T cells under radiotherapy
Radiotherapy (RT)-induced tumoricidal immunity is severely limited when tumors are well-established. Here, we report that depleting SIRPα on intratumoral macrophages augments efficacy of RT to eliminate otherwise large, treatment-resistant colorectal (MC38) and pancreatic (Pan02 and KPC) tumors, inducing complete abscopal remission and long-lasting humoral and cellular immunity that prevent recurrence. SIRPα-deficient macrophages activated by irradiated tumor-released DAMPs exhibit robust efficacy and orchestrate an anti-tumor response that controls late-stage tumors. Upon RT-mediated activation, intratumoral SIRPα-deficient macrophages acquire potent proinflammatory features and conduct immunogenic antigen presentation that confer a tumoricidal microenvironment highly infiltrated by tumor-specific cytotoxic T cells, NK cells and inflammatory neutrophils, but with limited immunosuppressive regulatory T cells, myeloid derived suppressor cells and post-radiation wound-healing. The results demonstrate that SIRPα is a master regulator underlying tumor resistance to RT and provide proof-of-principle for SIRPα-deficient macrophage-based therapies to treat a broad spectrum of cancers, including those at advanced stages with low immunogenicity and metastases.
- 28 May 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-16
Open AccessIntratumoral SIRPα-deficient macrophages activate tumor antigen-specific cytotoxic T cells under radiotherapy
Radiotherapy (RT)-induced tumoricidal immunity is severely limited when tumors are well-established. Here, we report that depleting SIRPα on intratumoral macrophages augments efficacy of RT to eliminate otherwise large, treatment-resistant colorectal (MC38) and pancreatic (Pan02 and KPC) tumors, inducing complete abscopal remission and long-lasting humoral and cellular immunity that prevent recurrence. SIRPα-deficient macrophages activated by irradiated tumor-released DAMPs exhibit robust efficacy and orchestrate an anti-tumor response that controls late-stage tumors. Upon RT-mediated activation, intratumoral SIRPα-deficient macrophages acquire potent proinflammatory features and conduct immunogenic antigen presentation that confer a tumoricidal microenvironment highly infiltrated by tumor-specific cytotoxic T cells, NK cells and inflammatory neutrophils, but with limited immunosuppressive regulatory T cells, myeloid derived suppressor cells and post-radiation wound-healing. The results demonstrate that SIRPα is a master regulator underlying tumor resistance to RT and provide proof-of-principle for SIRPα-deficient macrophage-based therapies to treat a broad spectrum of cancers, including those at advanced stages with low immunogenicity and metastases.
- 1 September 2015
- Published by Elsevier in Theriogenology
- Vol. 84 (4) , 583-588
Effects of dietary selenium on apoptosis of germ cells in the testis during spermatogenesis in roosters
- 1 September 2015
- Published by Elsevier in Theriogenology
- Vol. 84 (4) , 583-588
Effects of dietary selenium on apoptosis of germ cells in the testis during spermatogenesis in roosters
- 1 February 2011
- Published by Elsevier in Animal Reproduction Science
- Vol. 123 (3-4) , 187-191
Effects of maternal and dietary selenium (Se-enriched yeast) on the expression of p34cdc2 and CyclinB1 of germ cells of their offspring in goats
- 1 February 2011
- Published by Elsevier in Animal Reproduction Science
- Vol. 123 (3-4) , 187-191
Effects of maternal and dietary selenium (Se-enriched yeast) on the expression of p34cdc2 and CyclinB1 of germ cells of their offspring in goats